GlassScriptPhysician profile
Eric T Lubiner
NPI 1487645628
$2,901.96
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $295 · 2021: $177 · 2022: $579 · 2023: $878 · 2024: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.05 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $418.07 | 2019-2023 | Xgeva, Nplate, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $370.13 | 2019-2023 | Opdivo |
| Beigene USA, INC. | $319.18 | 2022-2023 | Brukinsa |
| Janssen Biotech, INC. | $218.42 | 2019-2024 | Erleada, Akeega, Rybrevant |
| Celgene Corporation | $160.07 | 2020-2023 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $139.40 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.23 | 2019-2021 | |
| Daiichi Sankyo INC. | $114.00 | 2023 | Enhertu |
| Genmab U.S., INC. | $103.79 | 2024 | Epkinly |
| Incyte Corporation | $102.35 | 2020-2023 | Jakafi |
| Rigel Pharmaceuticals, INC. | $92.67 | 2022 | |
| Genentech USA, INC. | $58.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $50.57 | 2022-2023 | Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $44.22 | 2022-2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $43.64 | 2019-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.00 | 2020-2023 | Keytruda, Lynparza |
| Seagen INC. | $39.13 | 2021-2023 | Adcetris |
| Genzyme Corporation | $36.61 | 2019-2022 | |
| Coherus Oncology, INC. | $36.12 | 2020-2023 | |
| Mirati Therapeutics, INC. | $30.80 | 2023 | Krazati |
| Tesaro, INC. | $29.63 | 2019 | |
| Gilead Sciences, INC. | $28.27 | 2021-2023 | Trodelvy |
| Agios Pharmaceuticals, INC. | $23.78 | 2023 | Pyrukynd |
| Pfizer INC. | $21.63 | 2020 | |
| Exelixis INC. | $20.98 | 2022 | |
| Emd Serono, INC. | $19.46 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $18.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2019 | |
| Puma Biotechnology, INC. | $17.26 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.05 | 2022 | |
| Novocure INC. | $16.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.19 | 2019 | |
| Astellas Pharma US INC | $15.67 | 2023 | Padcev |
| Dova Pharmaceuticals | $15.56 | 2019 | |
| Deciphera Pharmaceuticals INC. | $15.48 | 2022 | |
| Clovis Oncology, INC. | $15.28 | 2019 | |
| Aveo Pharmaceuticals, INC. | $13.86 | 2022 | |
| Taiho Oncology, INC. | $13.77 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lubiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.